# 2025-16273: FDA Tinkers with CAMZYOS Patent Clock for Extra Protection Time

2025-16273, Determination of Regulatory Review Period for Purposes of Patent Extension; CAMZYOS, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-26 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-16273
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-16273
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; CAMZYOS
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 41579
- Published: 2025-08-26
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Tinkers with CAMZYOS Patent Clock for Extra Protection Time

## Summary

The FDA updated the official review period for the drug CAMZYOS, which affects how long its patent can be extended. This change helps the company get extra time to protect their invention after the government’s review. If you’re involved in drug patents or development, this tweak could impact timing and market exclusivity.

## Abstract

The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of February 29, 2024. After review of the calculation of the applicable regulatory review period of the biologic product CAMZYOS (U.S. patent numbers 9,181,200; 9,585,883) in that notice, FDA has determined that a revision of the supplementary information section is warranted. This notice corrects the applicable regulatory review period language.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-16273 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/26/2025-16273/determination-of-regulatory-review-period-for-purposes-of-patent-extension-camzyos)
- [2025-16273 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-26/pdf/2025-16273.pdf)

## Related
- [Previous: 2025-16272, Determination of Regulatory Review Period for Purposes of Patent Extension; OHT…](https://policyrisk.com/federal-register/2025-16272)
- [Next: 2025-16274, Determination of Regulatory Review Period for Purposes of Patent Extension; PIA…](https://policyrisk.com/federal-register/2025-16274)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-16273 (as of 2026-06-08).
